Skip to main content

IDFC net loss narrows to Rs 147 crore in September quarter

Expenses during the second quarter of 2020-21 stood at Rs 55.70 crore, against Rs 65.95 crore a year ago.

IDFC Ltd on November 10 reported narrowing of its consolidated net loss to Rs 146.68 crore in the second quarter ended September 30. It had posted a net loss of Rs 407 crore in the corresponding quarter of the previous financial year. Sequentially, the losses widened against Rs 26.46 crore in the first quarter ended June 30.

However, Its total income during July-September 2020 grew 41.39 percent to Rs 91.54 crore as compared with Rs 64.74 crore in the year-ago period, IDFC Ltd said in a regulatory filing. Expenses during the second quarter of 2020-21 stood at Rs 55.70 crore, against Rs 65.95 crore a year ago.


On November 7, 2019, the group executed definitive agreements with Dharmesh Mehta and other investors for the sale of its entire investment in IDFC Securities Ltd. The sale was concluded in June 2020 after receiving all regulatory approvals. With the sale IDFC Securities Ltd, IDFC Securities (Singapore) Pte Ltd and IDFC Capital (USA) Inc have ceased to be subsidiaries of the group, it said in the filing.

Also, on October 31, 2019, the Monetary Authority of Singapore cancelled the capital market services licence issued to IDFC Capital (Singapore) Pte Ltd, wholly-owned subsidiary of IDFC Alternatives Ltd. The wholly-owned subsidiary is in the process of liquidation, it added.

Shares of IDFC Ltd on Tuesday rose 2.32 percent to Rs 30.90 apiece on the BSE.

Comments

Post a Comment

Popular posts from this blog

Panacea Biotech shares hit 5% upper circuit after dengue vaccine completes phase I & II study

DengiAIl induced robust neutralising antibody responses against all the four dengue virus serotypes, the company has said in an exchange filing. Panacea Biotech share price hit 5 percent upper circuit on the BSE on September 24 after the company completed phases I and II study of its dengue vaccine candidate DengiAIl. "Panacea Biotec Ltd. is delighted to announce the successful completion of its Phase I/II study to evaluate the safety and immunogenicity of its vaccine, DengiAll, a single-dose liveattenuated tetravalent vaccine," the company said in an exchange filing. Live-attenuated vaccines contain weakened bacteria or viruses that trigger an immune response but do not cause disease. The company said DengiAIl induced robust neutralising antibody responses against all the four dengue virus serotypes. DengiAIl has been found to be safe and well-tolerated with no serious adverse effects, the company said. After a single-dose, more than 80 percent of the participants ...
Post a Comment
Read more

Check Chemcon Speciality Chemicals IPO allotment status in four simple steps

Equity shares will get credited into the accounts of eligible investors by September 30 and the listing of equity shares will be on October 1, 2020. Chemcon Speciality Chemicals, the manufacturer for pharmaceutical and oilfields industries, is expected to announce the basis of allotment early next week. As per the schedule provided by the company, the finalisation of the basis of the allotment will be done by September 28 and the initiation of refunds or unblocking of funds from ASBA account will take place on September 29. Equity shares will get credited to the accounts of eligible investors by September 30 and the listing will be on October The IPO comprised a fresh issue of Rs 165 crore and an offer for sale of Rs 153 crore by promoters. The company will utilise fresh issue proceeds for expansion of manufacturing facility, working capital requirements, and general corporate purposes. Chemcon manufactures specialised chemicals, such as Hexamethyldisilazane (HMDS) and Chloromethyl Iso...
Post a Comment
Read more

Taking Stock | Profit-booking pulls Nifty below 14,450; Sensex drops 549 points

  All the sectoral indices ended in the red with IT and PSU bank indices falling 2 percent each. The market remained under pressure on January 15 on the back of profit-booking across sectors amid weak global cues. At close, the Sensex was down 549.49 points or 1.11% at 49,034.67, and Nifty was down 161.90 points or 1.11% at 14,433.70. "The market witnessed profit-booking and following global trends. Nifty continues to resist 14,600 and has taken a dip towards 14,360. If the market closes below 14,380 levels, we might see a correction till the levels of 14,180-14,200. Momentum indicators like RSI, MACD are indicating a small correction in the markets," said Ashis Biswas, Head of Research at CapitalVia Global Research. All the sectoral indices ended in the red with IT and PSU bank falling 2 percent each. Broader markets performed in line with the main indices with BSE Midcap and Smallcap indices falling 1 percent each. Tech Mahindra, GAIL, HCL Tech, Wipro and ONGC...
Post a Comment
Read more